Dashboard
1
Poor Management Efficiency with a low ROCE of 2.09%
- The company has been able to generate a Return on Capital Employed (avg) of 2.09% signifying low profitability per unit of total capital (equity and debt)
2
Poor long term growth as Net Sales has grown by an annual rate of -4.86% and Operating profit at -6.14% over the last 5 years
3
With a fall in Operating Profit of -66.65%, the company declared Very Negative results in Mar 25
4
Below par performance in long term as well as near term
Stock DNA
Pharmaceuticals & Biotechnology
CNY 3,865 Million (Small Cap)
15.00
NA
1.54%
0.01
5.79%
0.87
Revenue and Profits:
Net Sales:
461 Million
(Quarterly Results - Mar 2025)
Net Profit:
69 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
2.21%
0%
2.21%
6 Months
7.94%
0%
7.94%
1 Year
-7.6%
0%
-7.6%
2 Years
-2.74%
0%
-2.74%
3 Years
21.58%
0%
21.58%
4 Years
10.53%
0%
10.53%
5 Years
-27.81%
0%
-27.81%
Fuan Pharmaceutical (Group) Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News

Fuan Pharmaceutical's Valuation Adjustment Reveals Complex Financial Landscape and Challenges Ahead
Fuan Pharmaceutical (Group) Co., Ltd. has recently experienced a change in its evaluation, reflecting a shift in its valuation metrics. The company shows competitive ratios, including a P/E of 15 and a Price to Book Value of 0.87, but faces challenges with management efficiency and declining sales.
Read More Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-4.86%
EBIT Growth (5y)
-6.14%
EBIT to Interest (avg)
-1.18
Debt to EBITDA (avg)
0.18
Net Debt to Equity (avg)
0.01
Sales to Capital Employed (avg)
0.48
Tax Ratio
10.56%
Dividend Payout Ratio
21.26%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
2.09%
ROE (avg)
4.59%
Valuation key factors
Factor
Value
P/E Ratio
15
Industry P/E
Price to Book Value
0.87
EV to EBIT
25.63
EV to EBITDA
12.90
EV to Capital Employed
0.87
EV to Sales
1.93
PEG Ratio
NA
Dividend Yield
1.54%
ROCE (Latest)
3.40%
ROE (Latest)
5.79%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Sideways
Moving Averages
Bullish (Daily)
KST
Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
Mildly Bullish
Mildly Bullish
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Mar'25 - QoQ
Mar'25
Dec'24
Change(%)
Net Sales
461.20
388.90
18.59%
Operating Profit (PBDIT) excl Other Income
35.10
22.30
57.40%
Interest
1.90
5.20
-63.46%
Exceptional Items
0.10
-32.70
100.31%
Consolidate Net Profit
68.80
-23.70
390.30%
Operating Profit Margin (Excl OI)
76.10%
-72.70%
14.88%
USD in Million.
Net Sales
QoQ Growth in quarter ended Mar 2025 is 18.59% vs -29.93% in Dec 2024
Consolidated Net Profit
QoQ Growth in quarter ended Mar 2025 is 390.30% vs -127.43% in Dec 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
2,360.70
2,620.10
-9.90%
Operating Profit (PBDIT) excl Other Income
423.90
381.90
11.00%
Interest
23.80
30.40
-21.71%
Exceptional Items
-32.80
-235.20
86.05%
Consolidate Net Profit
278.20
234.40
18.69%
Operating Profit Margin (Excl OI)
95.20%
65.70%
2.95%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is -9.90% vs 9.20% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is 18.69% vs 16.73% in Dec 2023
About Fuan Pharmaceutical (Group) Co., Ltd. 
Fuan Pharmaceutical (Group) Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






